RxDoctor Payments Data

Andrew McFarland, MD

Retina Specialist · Winchester, VANPI 1538427471

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by AbbVie at 27.4% of the total. 2025 is the largest year on record at $227, more than ten times the $16 reported in 2019. That places this record below the midpoint for retina specialist clinicians in VA, where the typical reported total is $1,967.

$292in general payments, 2019–2025

Across 13 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$80
  • Apellis Pharmaceuticals, Inc.$79
  • Genentech USA, Inc.$59
  • ANI Pharmaceuticals, Inc.$43
  • Novartis$31

What the payments were for

  • Food & beverage$292100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$292 in reported general payments places this provider in the 10th percentile of 41 retina specialist providers in Virginia.

See all retina specialist providers in Virginia

Medicare billing

Part B allowed, 2024
$4,242,888
Medicare patients
1,113
Services billed
61,623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost17$4,064
Prednisolone Acetate108$3,975
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat58$1,256
Ketorolac Tromethamine57$948
Timolol Maleate14$640
Dexamethasone Sodium Phosphate11$539
Latanoprost33$538
Brimonidine Tartrate21$172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$80$4,06417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 41 retina specialist providers in Virginia.

Other retina specialist in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →